---
document_datetime: 2023-09-21 18:09:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/visudyne-epar-all-authorised-presentations_en.pdf
document_name: visudyne-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8577701
conversion_datetime: 2025-12-17 09:50:50.444835
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU)         | (Invented)   | Strength   | Pharmaceutical form     | Route of        | Immediate    | Content         | Pack size   |
|-----------------|--------------|------------|-------------------------|-----------------|--------------|-----------------|-------------|
| number          | name         |            |                         | administration  | packaging    | (concentration) |             |
| EU/1/00/140/001 | Visudyne     | 15 mg      | Powder for solution for | Intravenous use | vial (glass) | powder: 15 mg   | 1 vial      |
|                 |              |            | infusion                |                 |              |                 |             |